The African tree that could hold a cure for cancer

Scientists are going back to nature in their search for drugs against cancer and have found an African shrub which could offer a new weapon against the disease.

Tests on the drug, derived from the bark of the African bush willow, have shown that it attacks the blood supply to the cancer instead of the cancer cells themselves. A single dose can kill up to 95 per cent of solid tumour cells by starving them of their blood supply.

Dr Dai Chaplin, who led the research at the Cancer Research Campaign's Gray laboratories at Mount Vernon Hospital, Middlesex, said the drug's new type of action could have wide application. "As more than 90 per cent of cancers are solid tumours or lumps, we are very excited about its potential. It opens the door for the development of other drugs working on the same principle. Cancer is a war and we are opening up a new battlefront."

Announcing the findings at a press conference to mark National Cancer Day today, Professor Gordon McVie, director of the campaign, said cancer research had come full circle with a renewed interest in natural compounds after the fashionable swing away from them in the Seventies in favour of designer molecules dreamed up in the laboratory.

Professor Alan McGown of the Paterson Institute at the Christie hospital in Manchester, which is testing the anti-cancer properties of a range of natural compounds, said: "These are big complicated molecules - too big for a chemist to sit down and say `I am going to design that.' They would never have been discovered if we had not looked at nature. The world's greatest chemist of all time is nature."

Dr Chaplin said that most cancer treatments were targeted at killing the cancer cells. One centimetre of tumour can contain hundreds of millions of cells, making it a slow process requiring high doses of toxic drugs.

The new drug, combretastatin, destroys endothelial cells lining the blood vessels which supply the tumour. In laboratory studies, Dr Chaplin found that damaging one of these endothelial cells killed more than 1,000 tumour cells. The findings, published in the US journal, Cancer Research, showed only small doses were required reducing side-effects.

Dr Chaplin said: "The response can be dramatic. In some tumours it shuts down the blood supply in two hours. We may have a new class of drugs here. It is a great start."

Human trials could begin within 18 months. Dr Chaplin admitted there were many tests of safety and efficacy to be done before it could used on patients. The drug acts selectively, for reasons that are not understood, only targeting blood vessels in the tumour leaving others elsewhere in the body unaffected. It is not known, however, whether it will hinder the growth of blood vessels in other parts of the body, for example during wound healing or in the reproductive tract during ovulation and pregnancy.

Dr Chaplin also said that the drug killed the centre of the tumour but left the rim unaffected, and would therefore need to be used in conjunction with conventional radiotherapy or chemotherapy.

Combretastatin was discovered 10 years ago by Professor Bob Pettit of the Arizona State University in the US. Professor Pettit, who sits on the Cancer Research Campaign's drug committee, mentioned it to Dr Chaplin who decided to investigate its anti-cancer properties.

Leading article, page 19

Start your day with The Independent, sign up for daily news emails
Have you tried new the Independent Digital Edition apps?
ebooks
ebooksA special investigation by Andy McSmith
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Recruitment Genius: Bookkeeper / Office Co-ordinator

£9 per hour: Recruitment Genius: This role is based within a small family run ...

Recruitment Genius: Designer - Print & Digital

£28000 - £32000 per annum: Recruitment Genius: This Design and marketing agenc...

Recruitment Genius: Quantity Surveyor

£46000 per annum: Recruitment Genius: This property investment firm are lookin...

Recruitment Genius: Telesales / Telemarketing Executive - OTE £30k / £35k plus

£18000 - £35000 per annum: Recruitment Genius: This company specialises provid...

Day In a Page

The difference between America and Israel? There isn’t one

The difference between America and Israel? There isn’t one

Netanyahu knows he can get away with anything in America, says Robert Fisk
Families clubbing together to build their own affordable accommodation

Do It Yourself approach to securing a new house

Community land trusts marking a new trend for taking the initiative away from developers
Head of WWF UK: We didn’t send Cameron to the Arctic to see green ideas freeze

David Nussbaum: We didn’t send Cameron to the Arctic to see green ideas freeze

The head of WWF UK remains sanguine despite the Government’s failure to live up to its pledges on the environment
Author Kazuo Ishiguro on being inspired by shoot-outs and samurai

Author Kazuo Ishiguro on being inspired by shoot-outs and samurai

Set in a mythologised 5th-century Britain, ‘The Buried Giant’ is a strange beast
With money, corruption and drugs, this monk fears Buddhism in Thailand is a ‘poisoned fruit’

Money, corruption and drugs

The monk who fears Buddhism in Thailand is a ‘poisoned fruit’
America's first slavery museum established at Django Unchained plantation - 150 years after slavery outlawed

150 years after it was outlawed...

... America's first slavery museum is established in Louisiana
Kelly Clarkson: How I snubbed Simon Cowell and become a Grammy-winning superstar

Kelly Clarkson: How I snubbed Simon Cowell and become a Grammy-winning superstar

The first 'American Idol' winner on how she manages to remain her own woman – Jane Austen fascination and all
Tony Oursler on exploring our uneasy relationship with technology with his new show

You won't believe your eyes

Tony Oursler's new show explores our uneasy relationship with technology. He's one of a growing number of artists with that preoccupation
Ian Herbert: Peter Moores must go. He should never have been brought back to fail again

Moores must go. He should never have been brought back to fail again

The England coach leaves players to find solutions - which makes you wonder where he adds value, says Ian Herbert
War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

The battle for Mosul will unleash 'a million refugees'

Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn
Yvette Cooper: We can't lose the election. There's too much on the line

Yvette Cooper: We can't lose the election. There's too much on the line

The shadow Home Secretary on fighting radical Islam, protecting children, and why anyone in Labour who's thinking beyond May must 'sort themselves out'
A bad week for the Greens: Leader Natalie Bennett's 'car crash' radio interview is followed by Brighton council's failure to set a budget due to infighting

It's not easy being Green

After a bad week in which its leader had a public meltdown and its only city council couldn't agree on a budget vote, what next for the alternative party? It's over to Caroline Lucas to find out
Gorillas nearly missed: BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter

Gorillas nearly missed

BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
Downton Abbey effect sees impoverished Italian nobles inspired to open their doors to paying guests for up to €650 a night

The Downton Abbey effect

Impoverished Italian nobles are opening their doors to paying guests, inspired by the TV drama
China's wild panda numbers have increased by 17% since 2003, new census reveals

China's wild panda numbers on the up

New census reveals 17% since 2003